kabutan

JCR Pharmaceuticals Co.,Ltd.(4552) Summary

4552
TSE Prime
JCR Pharmaceuticals Co.,Ltd.
615
JPY
-43
(-6.53%)
Jan 29, 11:30 am JST
4.01
USD
Jan 28, 9:30 pm EST
Result
PTS
outside of trading hours
615.9
Jan 29, 11:29 am JST
Summary Chart Historical News Financial Result
PER
46.8
PBR
1.62
Yield
3.25%
Margin Trading Ratio
17.02
Stock Price
Jan 29, 2026
Opening Jan 29, 9:15 am
601 JPY 3.92 USD
Previous Close Jan 28
658 JPY 4.31 USD
High Jan 29, 10:32 am
624 JPY 4.08 USD
Low Jan 29, 9:15 am
591 JPY 3.86 USD
Volume
1,276,200
Trading Value
0.78B JPY 5.06M USD
VWAP
607.16 JPY 3.97 USD
Minimum Trading Value
61,500 JPY 401 USD
Market Cap
0.08T JPY 0.52B USD
Number of Trades
1,204
Liquidity & Number of Trades
As of Jan 29, 2026
Liquidity
High
1-Year Average
1,276
1-Year High Jun 2, 2025
15,312
Margin Trading
Date Short Interest Long Margin Positions Ratio
Jan 23, 2026 143,900 2,386,400 16.58
Jan 16, 2026 149,300 2,278,200 15.26
Jan 9, 2026 156,100 2,290,300 14.67
Dec 26, 2025 180,500 2,195,000 12.16
Dec 19, 2025 188,300 2,201,400 11.69
Company Profile
JCR Pharmaceuticals Co., Ltd. specializes in growth hormone products and focuses on biosimilars. The company collaborates with PeptiDream in creating carrier peptides.
Sector
Pharmaceuticals
JCR Pharmaceuticals Co., Ltd. develops, manufactures, and sells medical pharmaceuticals, regenerative medicine-related products, and pharmaceutical raw materials, primarily targeting rare disease areas. Through its group companies, the company engages in a wide range of activities including purchasing, facility management, market research, clinical trial supervision, pharmaceutical development, and intellectual property management. Internationally, JCR has subsidiaries in Brazil, Europe, and the United States, which handle clinical operations, regulatory affairs, and development tasks. The company also manages the distribution of pharmaceuticals and their raw materials, as well as contract manufacturing. JCR has affiliated companies involved in research and development, manufacturing, and sales in the regenerative medicine field, and has a proven track record in biosimilars.